NFC
VRNA

Northeast Financial Consultants’s Verona Pharma VRNA Stock Holding History

Northeast Financial Consultants’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,700
Closed -$404K – 294
2024
Q4 		$404K Hold
8,700
– – 0.02% 213
2024
Q3 		$250K Buy
+8,700
New +$214K 0.01% 251
2023
Q1 		– Sell
-8,700
Closed -$227K – 334
2022
Q4 		$227K Buy
+8,700
New +$116K 0.02% 282

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northeast Financial Consultants's VRNA Position: Q1 2025 in Review

Northeast Financial Consultants sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 8,700 shares — an estimated $404K sold.

Northeast Financial Consultants first reported a position in VRNA in Q4 2022 and held it in 3 quarters. The position peaked at $404K in Q4 2024. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

  • Northeast Financial Consultants reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
  • Northeast Financial Consultants sold 8,700 Verona Pharma shares in Q1 2025, an estimated $404K.
  • Northeast Financial Consultants first reported a position in Verona Pharma in Q4 2022 and held it in 3 quarters.
  • Northeast Financial Consultants's Verona Pharma position peaked at $404K in Q4 2024.
  • 258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Northeast Financial Consultants's 13F filing for Q1 2025, filed 16 May 2025.